Late-stage RSV vaccine trials show ‘exciting promise,’ some scientists say
0 minutes, 10 seconds Read
A Pfizer vaccine to protect older adults and infants from respiratory syncytial virus (RSV) infection has shown what some scientists are calling “exciting” promise in late-stage trials.
